BCPEM
SYRE icon

Bain Capital Public Equity Management’s Spyre Therapeutics SYRE Stock Holding History

Bain Capital Public Equity Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-384
Closed -$95K – 86
2018
Q1 		$95K Buy
+384
New +$69.4K 0.01% 66

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Bain Capital Public Equity Management's SYRE Position: Q2 2018 in Review

Bain Capital Public Equity Management sold out of Spyre Therapeutics (SYRE) in Q2 2018, closing a stake of 384 shares — an estimated $95K sold.

Bain Capital Public Equity Management first reported a position in SYRE in Q1 2018 and held it in 1 quarter. The position peaked at $95K in Q1 2018. 64 funds tracked by Wall St. Rank hold SYRE as of Q2 2018.

  • Bain Capital Public Equity Management reported no remaining Spyre Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 384 Spyre Therapeutics shares in Q2 2018, an estimated $95K.
  • Bain Capital Public Equity Management first reported a position in Spyre Therapeutics in Q1 2018 and held it in 1 quarter.
  • Bain Capital Public Equity Management's Spyre Therapeutics position peaked at $95K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.